Measurement of serotonin transporter binding with PET and [11C]MADAM:: A test-retest reproducibility study

被引:35
作者
Lundberg, Johan
Halldin, Christer
Farde, Lars
机构
[1] Karolinska Univ Hosp, Karolinska Inst, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, S-17176 Stockholm, Sweden
关键词
C-11]MADAM; positron emission tomography; serotonin transporter; reliability;
D O I
10.1002/syn.20297
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
[C-11]MADAM, or [C-11]N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine, is a radioligand suitable for positron emission tomography (PET) studies of the serotonin transporter (5-HTT) in man. The purpose of this study was to examine the test-retest reproducibility using a design tailored for future applied studies. Nine healthy male subjects were examined with PET and [C-11]MADAM under baseline conditions at two occasions 4-8 weeks apart. The subjects participated in a Phase 1 trial to which the present study was an addendum. Eight regions of interest were studied, including frontal cortex, hippocampal complex, and the raphe nuclei. All regions, but the raphe nuclei, were defined on MR-images to which the PET-images were coregistered using SPM2. Binding potentials were calculated using the simplified reference tissue model, with cerebellum as reference region. Test-retest data were calculated from the binding potentials, and included binding potential (BP) quotient, BP difference, and the intraclass correlation coefficient. The quotient was about one in all regions, and the mean difference varied between 0 and 11%. The intraclass correlation coefficient varied between 0.96 and 0.51 in the raphe nuclei and averaged bilateral regions. [C-11]MADAM was shown to have good to excellent reliability in measurements of 5-HTT binding in brain regions of interest in research on psychiatric disorders.
引用
收藏
页码:256 / 263
页数:8
相关论文
共 32 条
[1]
Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-lA receptors in the human brain [J].
Andrée, B ;
Hedman, A ;
Thorberg, SO ;
Nilsson, D ;
Halldin, C ;
Farde, L .
PSYCHOPHARMACOLOGY, 2003, 167 (01) :37-45
[2]
HIGH-AFFINITY [H-3] PAROXETINE BINDING TO SEROTONIN UPTAKE SITES IN HUMAN-BRAIN TISSUE [J].
BACKSTROM, I ;
BERGSTROM, M ;
MARCUSSON, J .
BRAIN RESEARCH, 1989, 486 (02) :261-268
[3]
CYTOARCHITECTURE OF THE HUMAN DORSAL RAPHE NUCLEUS [J].
BAKER, KG ;
HALLIDAY, GM ;
TORK, I .
JOURNAL OF COMPARATIVE NEUROLOGY, 1990, 301 (02) :147-161
[4]
Benmansour S, 1999, J NEUROSCI, V19, P10494
[5]
HEAD FIXATION DEVICE FOR REPRODUCIBLE POSITION ALIGNMENT IN TRANSMISSION CT AND POSITRON EMISSION TOMOGRAPHY [J].
BERGSTROM, M ;
BOETHIUS, J ;
ERIKSSON, L ;
GREITZ, T ;
RIBBE, T ;
WIDEN, L .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1981, 5 (01) :136-141
[6]
Diurnal variation in serotonin immunoreactivity in the dorsal raphe nucleus [J].
Birkett, M ;
Fite, KV .
BRAIN RESEARCH, 2005, 1034 (1-2) :180-184
[7]
Escitalopram [J].
Burke, WJ .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (10) :1477-1486
[8]
Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity [J].
Chalon, S ;
Tarkiainen, J ;
Garreau, L ;
Hall, H ;
Emond, P ;
Vercouillie, J ;
Farde, L ;
Dasse, P ;
Varnas, K ;
Besnard, JC ;
Halldin, C ;
Guilloteau, D .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (01) :81-87
[9]
COLLIGNON A, 1995, COMP IMAG VIS, V3, P263
[10]
AUTORADIOGRAPHY OF ANTIDEPRESSANT BINDING-SITES IN THE HUMAN-BRAIN - LOCALIZATION USING [H-3]IMIPRAMINE AND [H-3] PAROXETINE [J].
CORTES, R ;
SORIANO, E ;
PAZOS, A ;
PROBST, A ;
PALACIOS, JM .
NEUROSCIENCE, 1988, 27 (02) :473-496